Sector News

Sanofi blueprints hefty new Boston HQ with massive lease at Cambridge Crossing

December 19, 2018
Life sciences

Sanofi has picked the spot for its Massachusetts headquarters, once again planting its flag squarely in the Kendall Square neighborhood that’s the epicenter of biotech on the East Coast.

The French drugmaker inked a deal to anchor a new development in East Cambridge dubbed Cambridge Crossing, just a short walk from Sanofi Genzyme’s current home base on Kendall Square itself. The move will bring together 2,700 employees scattered around the state to two buildings on the new site, 900,000 square feet in all, a spokeswoman said.

Cambridge Crossing, self-described as “what bravery would look like if bravery were a place,” is a new 45-acre mixed-use development connected to Kendall Square. The site will feature lab space plus 11 acres of parks, housing and more. Healthcare firm Philips North America plans to move its U.S. headquarters there, as well. Aside from tech and lab space, the development will feature 2,400 residential units and 100,000 square feet of retail and dining space.

Sanofi employees in R&D, medical, commercial and global operations can look forward to the new digs, where they can collaborate more easily with not only their co-workers but industry colleagues—and potential partners—in the booming Boston biopharma ecosystem. Boston is rated a top life sciences cluster globally and Sanofi’s Genzyme has long contributed to the region’s knowledge base and standing.

In a statement, Sanofi Genzyme EVP Bill Sibold said the site “will further anchor us in this unique ecosystem of innovators for years to come.” He called the move a “critical investment” and said it’ll “allow us to reimagine the way we work together to develop transformative treatments for patients.”

Sanofi has 5,000 employees in Massachusetts, making it the largest life sciences employer in the state, the company said. The Boston Globe reports Sanofi’s lease is the biggest signed by a drugmaker in Boston since Vertex snapped up 1.1 million square feet in the city in 2011.

Sanofi’s lease comes shortly after the Globe reported Sanofi was eying a big expansion in Cambridge for its Genzyme unit; the actual move ended up being larger than the reported figure. Previously, the Globe reported the company was searching for 400,000 square feet for about 2,000 employees.

Sanofi is far from the only drugmaker to commit to the Boston area in a big way. Recently, Takeda said it would centralize its U.S. headquarters there, affecting 1,000 employees in suburban Chicago, where the company previously based its U.S. operations. Some employees will receive relocation offers in the move, a Takeda spokesperson said. Other drugmakers including Biogen and Pfizer are either headquartered or have significant operations in Boston.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”